Trial purpose
Cancer treatment
Tumor type
Breast
Age
18 - 75
Clinical summary
Summary
SNAC-2 is a national trial comparing two operations for detecting cancer cells in the lymph nodes of women with early breast cancer. The two operations are: 1) axillary clearance and 2) sentinel node biopsy. The standard of treatment for early stage breast cancer is axillary clearance which is the removal of most of the lymph nodes under the armpit (axilla). The new treatment is sentinel node biopsy where only the first few lymph nodes most closely related to the cancer are removed. We know that removing only the sentinel nodes may cause fewer side effects than doing an axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours.
Conditions
This trial is treating people with breast cancer
Eligibility
Inclusion
- Histologically or cytologically confirmed invasive breast cancer.
- Single or multiple ipsilateral primary breast cancer(s)
- Primary breast cancer may be less than or greater than 3cm.
Exclusion
In situ carcinoma only, clinically involved nodes where the investigator deems axillary clearance is essential, evidence of metastatic disease,previous breast cancer or in-situ carcinoma in the same breast.
Inclusion
- Your cancer has not spread to other parts of the body (localised).
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR *. View further details about this trial on the registry via the links below:
Trial sponsor
National Health & Medical Research Council (NHMRC)
Scientific Title
A randomised phase III study to determine in women with early breast cancer whether sentinel node based management increases the risk of loco-regional recurrence and in particular, axillary recurrence, compared with axillary clearance in any subgroup of women.
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information